IMV completes registered direct offering for proceeds of approximately US$9M

On December 20, 2022, IMV Inc. closed its previously announced registered direct offering for total gross proceed of approximately US$9M. 

IMV intends to use the net proceeds from the offering to continue the clinical development of its lead product candidate, maveropepimut-S, in diffuse large B cell lymphoma (DLBCL), ovarian cancer, the completion of its ongoing basket trial and to continue the development of its proprietary drug delivery platform (DPX®) and for general corporate purposes. 

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®

McCarthy Tétrault LLP advised IMV with a team led by Philippe Leclerc that included Mireille Trottier, Annie Poirier-Simard (Securities), Marie-Soleil Landry and Geneviève Favreau (Tax).